Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Junshi Bio Teams Up with IMCAS to Develop Neutralizing Antibodies for COVID-19

publication date: Mar 24, 2020

Junshi Biosciences of Shanghai signed a collaboration agreement with the Institute of Microbiology, Chinese Academy of Sciences (IMCAS) to partner development of neutralizing antibodies as a COVID-19 treatment. The two entities have already identified multiple strains of neutralizing antibodies (NAb) that block viral invasions in laboratory assays, and they have started animal experiments. Preliminary in vitro and in vivo studies have verified the NAbs' blocking activity. Junshi and IMCAS are confirming preclinical toxicology and in vivo activity with the goal of filing INDs in China and globally. More details....

Stock Symbol: (HK: 1877)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China